- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07273500
Precision Exercise in Obese Children With Bronchial Asthma
Precision Exercise Prescription for Obese Children With Bronchial Asthma: a Dose-dependent Study on Adiposity Biomarkers, Body Composition, and Respiratory Efficiency
This investigation recruited 72 pediatric patients with a confirmed bronchial asthma diagnosis. Participants were randomized into three cohorts: a control group undertaking under 75 minutes of weekly aerobic activity, a low-dose group completing 150 minutes/week, and a high-dose group performing 300 minutes/week. Exercise intensity was maintained between 50-70% of the age- adjusted maximum heart rate across 3-4 supervised sessions per week for a 12-week intervention period.
Pre- and post-intervention analyses included measurements of adipose-tissue- derived adipokines, circulating inflammatory markers, body composition, and pulmonary function parameters.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Population and Recruitment
A total of 72 pediatric patients with bronchial asthma were enrolled from the Pulmonary Medicine/Critical Care and Allergy-Immunology departments of King Khalid Hospital and two additional tertiary care centers in Riyadh, Saudi Arabia. Eligible participants were children aged 8 to 18 years with a diagnosis of moderate, clinically stable BA and a body mass index ranging from 30.0 to 35.0 kg/m². Further inclusion criteria stipulated the absence of lower limb or spinal deformities, stable medication regimens for the preceding three months, and no participation in structured physical activity for at least six months prior to the study. Exclusion criteria encompassed acute exacerbation of asthma symptoms, the presence of other chronic pulmonary diseases, and any pre- existing cardiovascular or musculoskeletal disorder that could impede exercise training.
Outcome Measures
Adiposity and Inflammatory Biomarkers: Serum concentrations of key adipokines-specifically total adiponectin, high-molecular-weight adiponectin, leptin, and resistin-were analyzed. Concurrently, systemic inflammatory mediators, including interleukin-6 and high-sensitivity C-reactive protein, were quantified using commercially available enzyme-linked immunosorbent assay kits.
Body Composition Analysis: A multi-frequency bioelectrical impedance analysis (BIA) device was employed to determine body composition indices. The parameters assessed included body fat percentage, fat mass, fat-free mass, total body water, and basal metabolic rate.
Pulmonary Function Testing: Spirometric evaluations were conducted with a calibrated spirometer to measure forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). The FEV1/FVC ratio was subsequently calculated from these values.
Intervention Protocol
All participants underwent a standardized respiratory re-training program for 12 consecutive weeks. This intervention was administered in 30-minute sessions, three times per week, and comprised diaphragmatic breathing, breath-holding and control exercises, pursed-lip breathing, inspiratory muscle strengthening, postural correction, and relaxation techniques.
Participants were then allocated into three distinct groups, each receiving an additional, varying dose of aerobic training superimposed on the core respiratory program:
Control Group: This group performed supplemental aerobic exercise at a moderate intensity (50-70% of age-predicted maximum heart rate) for a consistent total of less than 75 minutes per week, spread across three sessions.
Low-Dose Group: This cohort engaged in aerobic training at the same moderate intensity, with a target cumulative duration of 150 minutes per week. The duration was progressively increased from a baseline of 90 minutes in the first week by 30 minutes each subsequent week, stabilizing at the target dose by the third week.
High-Dose Group: This group followed the same moderate-intensity aerobic protocol but with a target weekly volume of 300 minutes. A similar progressive ramp-up was implemented, starting at 90 minutes weekly and increasing by 30 minutes per week until the target was achieved in the eighth week, after which it was maintained.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Riyadh Region
-
Al Kharj, Riyadh Region, Saudi Arabia
- Ragab K. Elnaggar
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age of 8-18 years
- Body mass index ranging from 30 to 35 kg/m2
- Verified asthma diagnosis per the Global Initiative for Asthma (GINA) criteria
- Moderate Onset
- Clinically Stable
- Maintained medication dosages in the past three months
- Free of lower limb or spinal deformities
- Not engaging in regular exercise regimens in the past six months.
Exclusion Criteria:
- Exacerbated asthma symptoms
- Chronic lung comorbidities
- Cardiovascular or musculoskeletal conditions expected to hinder the training.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Control group
The control group completed the 12-week respiratory re-training program alongside a moderate-intensity aerobic regimen (50-70% of maximum heart rate), maintaining a total weekly exercise volume not exceeding 75 minutes.
|
The standardized respiratory re-training protocol was administered in 30-minute sessions, three times per week, over a consecutive 12-week period.
The regimen incorporated diaphragmatic breathing, breath-holding and control techniques, pursed-lip breathing, respiratory muscle strengthening, postural correction, and relaxation exercises.
|
|
Experimental: Low-dose group
For the low-dose condition, participants engaged in the standard respiratory re training and supplemental aerobic exercise at 50-70% of maximum heart rate, capping the cumulative weekly duration at 150 minutes across the 12-week intervention.
|
A moderate-intensity aerobic regimen (50-70% of maximum heart rate) maintained at a consistent total weekly volume of 150 minutes.
|
|
Experimental: High-dose group
The high-dose group performed the core respiratory re-training in addition to a moderate-intensity aerobic regimen (50-70% of maximum heart rate), which was systematically escalated to a maintenance volume of 300 minutes per week throughout the 12-week trial.
|
A moderate-intensity aerobic regimen (50-70% of maximum heart rate) maintained at a consistent total weekly volume of 300 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Leptin
Time Frame: 2 months
|
Serum leptin concentration was evaluated as a primary adipokine.
It was assayed using a commercially available enzyme-linked immunosorbent assay kit, with pre- and post-training results expressed in nanograms per milliliter (ng/mL).
|
2 months
|
|
Total Adiponectin
Time Frame: 2 months
|
Serum total adiponectin concentration was quantified as a key adiposity biomarker, pre- and post-training.
It was measured using a commercially available enzyme-linked immunosorbent assay kit, with results reported in micrograms per milliliter (µg/mL)
|
2 months
|
|
High-molecular-weight Adiponectin
Time Frame: 2 months
|
The serum concentration of the high-molecular-weight isoform of adiponectin was analyzed pre- and post-training.
It was quantified using a commercial enzyme-linked immunosorbent assay, with levels reported in micrograms per milliliter (µg/mL).
|
2 months
|
|
Resistin
Time Frame: 2 months
|
Serum resistin concentration was assessed as an adipokine of interest.
Levels were determined from pre- and post-training blood samples using a commercial enzyme-linked immunosorbent assay kit, with concentrations reported in nanograms per milliliter (ng/mL).
|
2 months
|
|
Interleukin-6
Time Frame: 2 months
|
Systemic concentration of the inflammatory cytokine interleukin 6 was evaluated.
Pre- and post-training levels were quantified using a commercially available enzyme-linked immunosorbent assay kit, with results reported in picograms per milliliter (pg/mL).
|
2 months
|
|
High-sensitivity C-reactive protein
Time Frame: 2 months
|
Systemic concentration of high-sensitivity C-reactive protein was assessed as a marker of low-grade inflammation.
Pre- and post-training levels were quantified using a commercially available enzyme-linked immunosorbent assay kit, with results reported in milligrams per liter (mg/L).
|
2 months
|
|
Body fat percentage
Time Frame: 2 months
|
Body fat percentage was evaluated as a key body composition metric.
Pre- and post-training measurements were conducted using a bioelectrical impedance analysis device, with results expressed as a percentage (%).
|
2 months
|
|
Fat Mass
Time Frame: 2 months
|
Total body fat mass was assessed as a component of body composition.
It was measured pre- and post-intervention using a bioelectrical impedance analysis device, with values reported in kilograms (kg).
|
2 months
|
|
Fat-free mass
Time Frame: 2 months
|
Fat-free mass was evaluated as an indicator of lean body tissue.
Pre- and post-training measurements were obtained using a bioelectrical impedance analysis device, with results recorded in kilograms (kg).
|
2 months
|
|
Total body water
Time Frame: 2 months
|
Total body water was quantified as a fundamental body composition parameter.
Pre- and post-training measurements were conducted using a bioelectrical impedance analysis device, with results expressed in liters (L).
|
2 months
|
|
Basal Metabolic Rate
Time Frame: 2 months
|
Basal metabolic rate was estimated as a measure of resting energy expenditure.
Pre- and post-training assessments were conducted using a bioelectrical impedance analysis device, with results reported in kilocalories per day (kcal/day).
|
2 months
|
|
Forced Expiratory Volume in One Second
Time Frame: 2 months
|
Forced expiratory volume in one second (FEV#) was assessed as a primary spirometric parameter of airway function.
Pre- and post-training measurements were obtained using a calibrated spirometer, with results expressed as a percentage of the predicted value (% pred) based on established reference standards.
|
2 months
|
|
Forced Vital Capacity
Time Frame: 2 months
|
Forced vital capacity (FVC) was evaluated as a key measure of lung volume.
Pre- and post-training assessments were performed using a calibrated spirometer, with results expressed as a percentage of the predicted value (% pred).
|
2 months
|
|
Forced Expiratory Volume in One Second (FEV1) / Forced Vital Capacity (FVC) Ratio
Time Frame: 2 months
|
The ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC) was calculated as an indicator of airflow limitation.
This derived value was determined from pre- and post-training spirometric maneuvers and is expressed as a ratio (decimal value).
|
2 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RHPT/0023/041
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchial Asthma
-
Vanderbilt University Medical CenterWithdrawnAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
AstraZenecaActive, not recruitingBronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)Japan
-
Academisch Medisch Centrum - Universiteit van Amsterdam...ZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruitingSevere Asthma | Asthma Exacerbations | Bronchial ThermoplastyNetherlands
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SamA Pharmaceutical Co., LtdCompleted
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedAsthma, Bronchial | Bronchial AsthmaRussian Federation, Poland, Germany, Ukraine, Czech Republic
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedAsthma, Bronchial | Bronchial AsthmaRussian Federation, Hungary, Germany, Poland, Bulgaria, Ukraine, Czech Republic
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
Clinical Trials on Respiratory Re-training
-
Cairo UniversityCompletedBronchial AsthmaSaudi Arabia
-
Maged BashaCairo University; Prince Sattam Bin Abdulaziz UniversityCompleted
-
Nantes University HospitalCompleted
-
Royal Brompton & Harefield NHS Foundation TrustUnknown
-
Drexel UniversityNational Institute of Mental Health (NIMH)CompletedBinge-Eating Disorder | Bulimia Nervosa | Binge Eating | Bulimia; AtypicalUnited States
-
Cairo UniversityCompleted
-
Montiha AzeemRecruitingDiabetic Peripheral NeuropathyPakistan
-
University of North Carolina, Chapel HillNational Institute of Dental and Craniofacial Research (NIDCR)CompletedMandibular AdvancementUnited States
-
Emory UniversityNational Institute of Mental Health (NIMH)Completed
-
Uppsala UniversityFolksamCompletedComplex Regional Pain SyndromesSweden